EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials

Zoë C Cooper iD, Indira Garcia-Cordero, Maria Carmela Tartaglia, Adam M Staffaroni, Kevin Duff, Douglas Gunzler, Adam L Boxer, Anne-Marie Wills

Alzheimer's & Dementia · 2026

DOI: 10.1002/alz.71641 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Alzheimer's & Dementia, 2026. Verfasst von Zoë C Cooper und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Cognition, Supranuclear Palsy, Progressive. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Progressive supranuclear palsy (PSP) causes executive dysfunction, fluency deficits, and behavioral changes. We examined longitudinal changes in PSP cognition using the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). METHODS Using the RBANS and executive function and fluency tests from 486 and 377 participants in the PASSPORT (NCT03068468) and tilavonemab (NCT02985879) clinical trials, we assessed linear mixed models of cognitive subtest score change, controlling for disease duration, age, sex, and treatment group. RESULTS The greatest declines occurred in subtests assessing visuospatial (figure copy, figure recall), executive function (Color Trails, coding), and fluency (primarily semantic fluency), although controlling for motor and ocular motor disability reduced the magnitude of score decline. Subtests assessing immediate and delayed memory (story recall, story memory, list recall, list recognition) declined slowly or not at all. DISCUSSION Cognition in PSP is characterized by declines in executive, visuospatial function, and fluency, with relative preservation of memory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CognitionSupranuclear Palsy, ProgressiveAgedFemaleHumansMaleMiddle AgedExecutive FunctionLongitudinal StudiesNeuropsychological Tests

Stichwörter der Autor:innen

Color TrailsRepeatable Battery for the Assessment of Neuropsychological Status (RBANS)cognitioncognitive declineexecutive functionfluencymemoryprogressive supranuclear palsy (PSP)visuospatial function

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Cognitive Neuroscience Center, Universidad de San Andrés, Buenos Aires, Argentina.
  • National Scientific and Technical Research Council (CONICET), Buenos Aires, Argentina.
  • Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada.
  • Fein Memory and Aging Center, Department of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, California, USA.

ORCID-Profile: Zoë C Cooper

Förderung

  • U.S. Food and Drug Administration

Zitieren

APA

Cooper, Z. C., Garcia-Cordero, I., Tartaglia, M. C., Staffaroni, A. M., Duff, K., Gunzler, D., Boxer, A. L., & Wills, A. M. (2026). Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials. Alzheimer's & Dementia. https://doi.org/10.1002/alz.71641

Vancouver

Cooper ZC, Garcia-Cordero I, Tartaglia MC, Staffaroni AM, Duff K, Gunzler D, et al. Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials. Alzheimer's & Dementia. 2026. doi:10.1002/alz.71641

BibTeX
@article{Cooper2026,
  author = {Cooper, Zoë C and Garcia-Cordero, Indira and Tartaglia, Maria Carmela and Staffaroni, Adam M and Duff, Kevin and Gunzler, Douglas and Boxer, Adam L and Wills, Anne-Marie},
  title = {Longitudinal cognitive outcomes in two progressive supranuclear palsy clinical trials},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  doi = {10.1002/alz.71641}
}
Kostenlos starten →